Survodutide

Also known as: BI 456906

Weight Loss Phase 3 Trials

GLP-1/Glucagon dual receptor agonist

Mechanism of Action

Activates GLP-1 and glucagon receptors; the glucagon arm aims to raise energy expenditure on top of appetite suppression. In Phase 3 trials for obesity and MASH.

287

Community Posts

86

Users Discussing

29

Research Articles

20

Clinical Trials

Reported Outcomes

Clinical grade reflects published research; Community grade reflects user reports (n=287).

Outcome

Clinical

Community

Reported by

Sleep Quality

Effects on sleep quality

Clinical: C

Community: B

27% (29)

Weight Loss

Reduction in body weight

Clinical: B

Community: B

19% (27)

Cardiovascular

Effects on heart health markers

Clinical: B

Community: B

16% (16)

Energy Levels

Changes in energy and fatigue levels

Clinical: D

Community: B

15% (20)

Appetite Suppression

Reduced hunger and food cravings

Clinical: C

Community: B

12% (11)

Blood Sugar Control

Improved glycemic control and insulin sensitivity

Clinical: A

Community: C

9% (11)

Mental/Mood

Effects on mood and cognitive function

Clinical: C

Community: B

6% (6)

Who Discusses Survodutide

From community reports with demographic data.

Gender

Female 50%

Male 50%

n=16

Side Effects

Limited data

Based on 19 user reports (n=19). Frequency indicates how often each was mentioned.

Common (>5%)

Fatigue

Mild 5 reports 22.7%

Nausea

Mild 2 reports 9.1%

Weight Loss Stall

Mild 2 reports 9.1%

Food Noise

Mild 2 reports 9.1%

Tiredness

Mild 2 reports 9.1%

Constipation

Mild 2 reports 9.1%

Low Energy

Mild 2 reports 9.1%

Uncommon (1-5%)

Body Dysmorphia

Mild 1 reports 4.5%

Loose Skin

Mild 1 reports 4.5%

Gut Pain

Mild 1 reports 4.5%

Gastrointestinal Issues

Mild 1 reports 4.5%

Weight Loss Plateau

Mild 1 reports 4.5%

Heartburn

Mild 1 reports 4.5%

Gerd

Mild 1 reports 4.5%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

i

Gastrointestinal Issues

5 mentions

GI side effects are the most commonly reported. Usually improve over time with slow titration.

i

Injection Site Reactions

5 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose: 0.6-1mg weekly (research/trial protocols)
Titration: Titrate slowly over weeks based on tolerance
Half-life: ~6-7 days (estimated)
Administration: Subcutaneous injection, once weekly

Community Dosing Patterns

Based on 22 mentions

Community-reported patterns, not medical advice.

4mg weekly

1

1mg weekly

1

3mg EOD

1

2mg 3 days after Tirzepatide

1

0.6mg weekly

1

Research

29

Total Articles

20

Clinical Trials

16

Reviews

Key Studies

Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a ran Clinical Trial

Diabetologia (2024)

Correction to: Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 Clinical Trial

Diabetologia (2024)

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Clinical Trial

Obesity (Silver Spring) (2025)

Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, Clinical Trial

Diabetes Obes Metab (2025)

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m(2) in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist. Clinical Trial

Diabetes Obes Metab (2025)

Commonly Stacked With

From community members' documented stacks involving Survodutide.

Tirzepatide 51 stacks (82.3%)

Cagrilintide 12 stacks (19.4%)

Retatrutide 8 stacks (12.9%)

Switching Patterns

Based on 27 discussions about switching to or from Survodutide.

→ Switching FROM

Retatrutide 5 mentions

Users who switched to Survodutide

← Switching TO

Retatrutide 5 mentions

Users who switched from Survodutide